Tafasitamab
Showing 26 - 38 of 38
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (tafasitamab, parsaclisib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma
- tafasitamab
- parsaclisib
-
Birmingham, Alabama
- +49 more
Sep 21, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- +2 more
- Tafasitamab
- +2 more
-
Jacksonville, Florida
- +16 more
Dec 10, 2021
Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)
Recruiting
- Relapsed/Refractory
- Tafasitamab
- +8 more
-
Santa Fe, CaliforniaCalifornia Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022
DLBCL Trial (Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day
Approved for marketing
- DLBCL
- Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
- (no location specified)
Aug 26, 2020
Relapsed or Refractory DLBCL Trial in United States (Selinexor, Rituximab, Bendamustine)
Suspended
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Selinexor
- +9 more
-
Tucson, Arizona
- +17 more
Jan 24, 2023
Diffuse Large B-cell Lymphoma Trial in Worldwide (Rituximab (RTX), Tafasitamab, Bendamustine (BEN))
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab (RTX)
- +2 more
-
Anaheim, California
- +157 more
Aug 1, 2022
Diffuse Large B-cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide, Rituximab)
Recruiting
- Diffuse Large B-cell Lymphoma
- Tafasitamab
- +8 more
-
Birmingham, Alabama
- +408 more
Aug 23, 2022
Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (tafasitamab, rituximab, lenalidomide)
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- tafasitamab
- +3 more
-
Concord, California
- +255 more
Dec 1, 2022
Lenalidomide Monotherapy in R/R DLBCL
Completed
- Diffuse Large B Cell Lymphoma
-
Rochester, Minnesota
- +56 more
Aug 23, 2022
Diffuse Large B-cell Lymphoma Trial in Worldwide (MOR00208, Lenalidomide)
Active, not recruiting
- Diffuse Large B-cell Lymphoma
-
Bakersfield, California
- +52 more
Sep 1, 2021
Systemic Therapies for R/R DLBCL
Completed
- Diffuse Large B Cell Lymphoma
-
Scottsdale, Arizona
- +165 more
Oct 12, 2021